celecoxib treatment alters p53 and mdm2 expression via cox-2 crosstalk in a549 cells

Authors

mehdi gharghabi department of toxicology-pharmacology, school of pharmacy, tehran university of medical sciences, tehran, iran

farhang rezaei department of toxicology-pharmacology, school of pharmacy, tehran university of medical sciences, tehran, iran

fereshteh mir mohammadrezaei department of biology, faculty of science, university of mazandaran, mazandaran, babolsar, iran

mohammad hossein ghahremani tehran university of medical sciences

abstract

cyclooxygenase-2 (cox-2) has a pivotal role in the pathogenesis of the lung cancer. it is known that cox-2 negatively regulates the activity of a number of tumor suppressors, including p53. consequently, inhibition of cox-2 signaling is anticipated to be a promising approach to stabilize p53 functionality. in this regard, we investigated the effect of cox-2 signaling blockade on p53 and cox-2 expression in a549 cells. cell viability was assessed using mtt and protein expression was measured using western blot assay. results revealed that celecoxib dose-dependently induced growth inhibition within 24h. however, prolonged exposure to the drug up to 48h led to increase cell viability compared to the corresponding control. western blot analyses demonstrated that celecoxib could augment p53 expression within 24h, independently of cox-2 inhibition. in contrast, celecoxib treatment not only returned p53 to the control level, but also strikingly induce cox-2 expression within 48h. of further relevance, celecoxib exposure could significantly result in mdm2 elevation at 48h. these findings represent p53 as a molecular target being interconnected with cox-2 signaling axis upon celecoxib treatment. moreover, our data point toward the possibility that celecoxib treatment may not be a proper therapeutic strategy in lung cancer cells owing to its potential role in the activation of oncogenes, including cox-2 and mdm2 which seemingly confers a chemoresistance circumstance to the cell. consequently, these results underscore intensive preclinical assessment prior to applying cox-2 inhibitors in the treatment of lung tumors.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells

Cyclooxygenase-2 (COX-2) has a pivotal role in the pathogenesis of the lung cancer. It is known that COX-2 negatively regulates the activity of a number of tumor suppressors, including p53. Consequently, inhibition of COX-2 signaling is anticipated to be a promising approach to stabilize p53 functionality. In this regard, we investigated the effect of COX-2 signaling blockade on p53 and COX-2 e...

full text

Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells

Cyclooxygenase-2 (COX-2) has a pivotal role in the pathogenesis of the lung cancer. It is known that COX-2 negatively regulates the activity of a number of tumor suppressors, including p53. Consequently, inhibition of COX-2 signaling is anticipated to be a promising approach to stabilize p53 functionality. In this regard, we investigated the effect of COX-2 signaling blockade on p53 and COX-2 e...

full text

Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells

Cyclooxygenase-2 (COX-2) has a pivotal role in the pathogenesis of the lung cancer. It is known that COX-2 negatively regulates the activity of a number of tumor suppressors, including p53. Consequently, inhibition of COX-2 signaling is anticipated to be a promising approach to stabilize p53 functionality. In this regard, we investigated the effect of COX-2 signaling blockade on p53 and COX-2ex...

full text

Runx3 Expression Inhibits Proliferation and Distinctly Alters mRNA Expression of Bax in AGS and A549 Cancer Cells

Runx3, a member of Runt-related transcription factor (Runx) proteins with tumor suppressor effect, is a tissue–restricted and cancer related transcription factor that regulate cell proliferation and growth, as well as differentiation. In the present study, exogenous Run3 was transiently expressed in AGS (human gastric adenocarcinoma), with undetectable Runx3 protein and in A549 (human lung carc...

full text

Runx3 Expression Inhibits Proliferation and Distinctly Alters mRNA Expression of Bax in AGS and A549 Cancer Cells

Runx3, a member of Runt-related transcription factor (Runx) proteins with tumor suppressor effect, is a tissue–restricted and cancer related transcription factor that regulate cell proliferation and growth, as well as differentiation. In the present study, exogenous Run3 was transiently expressed in AGS (human gastric adenocarcinoma), with undetectable Runx3 protein and in A549 (human lung carc...

full text

Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms.

Celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers. The aim of this study was to clarify the mechanism of action of celecoxib in canine mammary tumors. We examined the antitumor effects of celecoxib in AZACB canine mammary tumor cells expressing low levels of cyclooxygenase‑2 (COX‑2) to minimize the effect of COX‑2 on its activity. Our data revealed that celec...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of pharmaceutical research

جلد ۱۵، شماره ۲، صفحات ۴۸۳-۴۸۹

Keywords
[ ' p 5 3 ' , ' c o x ' , 2 , ' c r o s s t a l k ' , ' c e l e c o x i b ' ]

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023